gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 25 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIAID NIH HHS
Grant: R01 AI060866
NCI NIH HHS
Grant: P30 CA008748
NIAID NIH HHS
Grant: R01 AI084178
NCI NIH HHS
Grant: R01 CA235667
NCI NIH HHS
Grant: R01 CA236615
National Institutes of Health
Grant: 5R01CA236615-02
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
National Institutes of Health
Grant: 5R01CA235667-02
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
National Institutes of Health
Grant: 5R01AI060866-02
gC1q-R/p33: structure function and role on inflammation.
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
Fields of Study
Keywords
Sustainable Development Goals